diazoxide has been researched along with Dementia Praecox in 2 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of this study present a novel application for potassium channel openers/activators in the neuropsychiatric disorders and diazoxide may be an effective adjuvant agent in the management of schizophrenia." | 9.10 | Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia. ( Akhondzadeh, S; Amini-Nooshabadi, H; Kamalipour, A; Mirsepassi, GR; Moin, M; Mojtahedzadeh, V, 2002) |
| "The results of this study present a novel application for potassium channel openers/activators in the neuropsychiatric disorders and diazoxide may be an effective adjuvant agent in the management of schizophrenia." | 5.10 | Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia. ( Akhondzadeh, S; Amini-Nooshabadi, H; Kamalipour, A; Mirsepassi, GR; Moin, M; Mojtahedzadeh, V, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akhondzadeh, S | 1 |
| Mojtahedzadeh, V | 1 |
| Mirsepassi, GR | 1 |
| Moin, M | 1 |
| Amini-Nooshabadi, H | 1 |
| Kamalipour, A | 1 |
| Zhang, L | 1 |
| Li, X | 1 |
| Zhou, R | 1 |
| Xing, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pathophysiological Study to Determine if Enhancing Glutamate Transporter Function Produces Antidepressant Effects in Patients With Major Depressive Disorder[NCT02049385] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2014-01-03 | Terminated (stopped due to Severe side effects & lack of target engagement) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in Montgomery Asberg Depression Rating Scale (MADRS) from baseline to 7 days post-treatment. The range of values is from 0 - 60, with a higher score indicating increased depressive symptoms. A score of 7-19 indicates mild depression; 20-34 indicates moderate depression; >34 indicates severe depression. (NCT02049385)
Timeframe: 7 days
| Intervention | percentage of change in units of scale (Median) |
|---|---|
| Diazoxide | 0 |
| Placebo | 10 |
1 trial available for diazoxide and Dementia Praecox
| Article | Year |
|---|---|
Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Diazoxide; Double-Blind Method; Drug | 2002 |
1 other study available for diazoxide and Dementia Praecox
| Article | Year |
|---|---|
Possible role of potassium channel, big K in etiology of schizophrenia.
Topics: Animals; Brain; Diazoxide; Dopamine; gamma-Aminobutyric Acid; Humans; Large-Conductance Calcium-Acti | 2006 |